Reistone Announces First Patient Dosed in Phase III Global Study in Atopic Dermatitis

Retrieved on: 2021-05-13 12:00:00

Tags for this article:

Branches of biology

Type I hypersensitivity

Signal transduction

Biology

Medical specialties

Janus kinase inhibitor

JAK-STAT signaling pathway

Reistone Biopharma Company Limited

Shanghai

China

Click the tags to see associated articles and topics

Reistone Announces First Patient Dosed in Phase III Global Study in Atopic Dermatitis. View article details on HISWAI: https://www.biospace.com/article/releases/reistone-announces-first-patient-dosed-in-phase-iii-global-study-in-atopic-dermatitis/

Excerpt

SHANGHAI, May 13, 2021 /PRNewswire/ -- Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused ...

Article found on: www.biospace.com

View Original Article